Market data not licensed for redistribution.
Orum Therapeutics
475830 ยท KOSDAQ ยท Manufacture of Basic Pharmaceutical Products
Close
Source: Financial Services Commission stock price data (data.go.kr), updated once a day.
Daily price, 1 year
Key statistics
Market cap (KRW bn)โ
PERโ
PBRโ
ROE %10.0
Debt ratio % (liabilities / equity)57
Revenue TTM (KRW bn)0.0
Op. profit TTM (KRW bn)-65.6
Dividend yield %โ
Basis: market cap at โฆ; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.
Upcoming risk events
Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.
No scheduled risk events found (last checked 2026-10-30 19:40 KST).
Annual results (KRW bn)
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | โ | โ | โ | 20.9 | 0.0 |
| Operating profit | โ | โ | โ | -8.3 | -51.8 |
| Net income | โ | โ | โ | -5.7 | -42.0 |
Quarterly results (KRW bn, 3 months)
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 | |
|---|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating profit | -9.6 | -10.0 | -13.9 | -18.3 | -18.1 | -15.4 |
| Net income | -8.6 | -3.8 | -13.6 | -16.0 | -15.3 | 63.4 |
Largest shareholder
As of the 2025 annual report: ์ด์น์ฃผ and related parties hold 16.40% of common shares.
Recent disclosures
| Date | Filing | Summary | |
|---|---|---|---|
| 2026-10-29 | Insider / major-holder ownership report ์์ใ์ฃผ์์ฃผ์ฃผํน์ ์ฆ๊ถ๋ฑ์์ ์ํฉ๋ณด๊ณ ์ | DART original | |
| 2026-10-23 | Shareholder meeting ์์์ฃผ์ฃผ์ดํ๊ฒฐ๊ณผ | DART original | |
| 2026-10-23 | Governance / misc. (routine) ์ฃผ์๋งค์์ ํ๊ถ๋ถ์ฌ์๊ดํ์ ๊ณ | DART original | |
| 2026-10-23 | Governance / misc. (routine) ๋ ๋ฆฝ์ด์ฌ์์ ์ใํด์๋๋์ค๋ํด์์๊ดํ์ ๊ณ | DART original | |
| 2026-10-22 | Shareholder meeting [๊ธฐ์ฌ์ ์ ]์ฃผ์ฃผ์ดํ์์ง๊ณต๊ณ | DART original | |
| 2026-10-21 | Insider / major-holder ownership report ์ฃผ์๋ฑ์๋๋๋ณด์ ์ํฉ๋ณด๊ณ ์(์ผ๋ฐ) | DART original | |
| 2026-10-08 | Shareholder meeting ์ฃผ์ฃผ์ดํ์์ง๊ณต๊ณ | DART original | |
| 2026-09-17 | Clinical trial / regulatory approval ํฌ์ํ๋จ๊ด๋ จ์ฃผ์๊ฒฝ์์ฌํญ (Bristol Myers Squibb(BMS)์ BMS-986497(ORM-6151) ์์ ์ค๋จ์ ๋ฐ๋ฅธ ์์ฐ์์๋ ๊ณ์ฝ ์ข ๋ฃ) | DART original | |
| 2026-09-10 | Shareholder meeting ์ฃผ์ฃผ๋ช ๋ถํ์๊ธฐ๊ฐ๋๋๊ธฐ์ค์ผ์ค์ | DART original | |
| 2026-09-10 | Shareholder meeting ์ฃผ์ฃผ์ดํ์์ง๊ฒฐ์ (์์์ฃผ์ฃผ์ดํ) | DART original | |
| 2026-08-31 | IR event ๊ธฐ์ ์ค๋ช ํ(IR)๊ฐ์ต | DART original | |
| 2026-08-18 | CB conversion / price adjustment ์ ํ์ฃผ์์์ ํ๊ฐ์ก์กฐ์ (์ ํ์ฐ์ ์ฃผ) | DART original |
Past material filings and price reaction (market-adjusted)
| Date | Filing type | On the news (vs. market) | Next day (vs. market) | 20 days (vs. market) |
|---|---|---|---|---|
| 2026-09-17 | Clinical trial / regulatory approval | -31.2% | +0.7% | โ |
| 2026-03-05 | Revenue/profit change >=30% (15% large caps) | -0.1% | -1.3% | -25.4% |
| 2025-12-18 | Rights offering (paid-in capital increase) | +7.8% | +10.0% | +9.0% |
| 2025-04-28 | Clinical trial / regulatory approval | -28.6% | +7.1% | +12.8% |
| 2025-03-13 | Revenue/profit change >=30% (15% large caps) | -2.5% | +9.7% | +1.2% |
For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer โ Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view